ORIC Pharmaceuticals (ORIC) News Today $10.77 -0.38 (-3.41%) Closing price 04:00 PM EasternExtended Trading$10.67 -0.10 (-0.89%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period ORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesJanuary 27 at 4:15 PM | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 5.6% - Should You Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Up 5.6% - Here's What HappenedJanuary 23, 2025 | marketbeat.comCantor Fitzgerald Estimates ORIC FY2025 EarningsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for ORIC Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings of (January 23, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 7.8% - Should You Sell?ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 7.8% - Here's WhyJanuary 16, 2025 | marketbeat.comEquities Analysts Issue Forecasts for ORIC Q2 EarningsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Analysts at HC Wainwright dropped their Q2 2025 EPS estimates for shares of ORIC Pharmaceuticals in a report released on Monday, January 13th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.5January 16, 2025 | marketbeat.comORIC Pharma Stock Climbs On Clinical Supply Deal With J&J's Janssen For ORIC-114January 14, 2025 | markets.businessinsider.comOric Pharmaceuticals announces clinical supply agreement with JanssenJanuary 14, 2025 | finance.yahoo.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 10.9% Higher - Time to Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 10.9% Higher - Here's What HappenedJanuary 14, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday.January 14, 2025 | marketbeat.comOric Pharmaceuticals: Promising Clinical Outcomes and Strategic Advancements Support Buy RatingJanuary 14, 2025 | markets.businessinsider.comOric Pharmaceuticals provides early Phase 1b combination data for ORIC-944January 13, 2025 | markets.businessinsider.comORIC Pharmaceuticals (NASDAQ:ORIC) Earns Outperform Rating from WedbushWedbush reissued an "outperform" rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a report on Monday.January 13, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Here's WhyORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - What's Next?January 13, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research note on Monday.January 13, 2025 | marketbeat.comORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming MilestonesJanuary 13, 2025 | globenewswire.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from AnalystsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has been given a consensus recommendation of "Buy" by the eight research firms that are covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average twelve-month price target aJanuary 12, 2025 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)January 10, 2025 | markets.businessinsider.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 8.8% - Here's WhyORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 8.8% - What's Next?January 8, 2025 | marketbeat.comORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | finance.yahoo.comORIC Pharmaceuticals (NASDAQ:ORIC) Sees Unusually-High Trading Volume - What's Next?ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume Increase - Here's WhyJanuary 7, 2025 | marketbeat.comORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down - Here's What HappenedORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down - Time to Sell?December 26, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 3.4% - Here's What HappenedORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 3.4% - Time to Sell?December 24, 2024 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by State Street CorpState Street Corp decreased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 14.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,938,169 shares of the company's stockDecember 24, 2024 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Holdings Raised by Franklin Resources Inc.Franklin Resources Inc. lifted its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 26.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 950,459 shares of the company's stock after acquiringDecember 22, 2024 | marketbeat.comPratik S. Multani Sells 8,850 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) StockDecember 18, 2024 | insidertrades.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Recommendation of "Buy" from AnalystsShares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have earned an average recommendation of "Buy" from the eight brokerages that are covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price target among aDecember 18, 2024 | marketbeat.comPratik S. Multani Sells 8,850 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) StockORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) insider Pratik S. Multani sold 8,850 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,278.00. Following the transaction, the insider now directly owns 46,765 shares in the company, valued at $387,214.20. The trade was a 15.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.December 17, 2024 | marketbeat.comDominic Piscitelli Sells 8,851 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) StockORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 8,851 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,286.28. Following the completion of the sale, the chief financial officer now directly owns 106,764 shares of the company's stock, valued at $884,005.92. This represents a 7.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.December 17, 2024 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Sells $204,184.80 in StockORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CEO Jacob Chacko sold 24,660 shares of ORIC Pharmaceuticals stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total transaction of $204,184.80. Following the transaction, the chief executive officer now directly owns 778,648 shares in the company, valued at $6,447,205.44. This represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.December 17, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down - Time to Sell?ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down - Here's What HappenedDecember 16, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Boosts Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Charles Schwab Investment Management Inc. raised its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 152.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 410,229 shares of the companyDecember 14, 2024 | marketbeat.comFmr LLC Decreases Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Fmr LLC reduced its position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 11.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,378,819 shares of the company's stock after selling 541,54December 8, 2024 | marketbeat.comArrowMark Colorado Holdings LLC Acquires 80,986 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)ArrowMark Colorado Holdings LLC lifted its holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 6.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,354,508 shares of the company's stock afterDecember 3, 2024 | marketbeat.comFred Alger Management LLC Has $2.25 Million Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Fred Alger Management LLC boosted its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 40.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 219,447 shares of the company's stock after purchasing an aDecember 2, 2024 | marketbeat.comAlkeon Capital Management LLC Has $40.02 Million Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Alkeon Capital Management LLC lifted its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 2.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,904,096 shares of the company's stock after buying an additioNovember 29, 2024 | marketbeat.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 25, 2024 | globenewswire.comFirst Turn Management LLC Sells 64,923 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)First Turn Management LLC lessened its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,451,037 shares ofNovember 19, 2024 | marketbeat.comResearch Analysts Issue Forecasts for ORIC FY2024 EarningsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2024 earnings estimates for shares of ORIC Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst P. Agrawal now anticipates tNovember 18, 2024 | marketbeat.comFY2024 EPS Estimate for ORIC Pharmaceuticals Cut by AnalystORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Investment analysts at Wedbush decreased their FY2024 EPS estimates for ORIC Pharmaceuticals in a report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.82) per shNovember 15, 2024 | marketbeat.comOric Pharmaceuticals Reports Strong Financial Growth and Clinical ProgressNovember 14, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)November 13, 2024 | markets.businessinsider.comORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational UpdatesNovember 13, 2024 | markets.businessinsider.comPositive Outlook on ORIC-114: Promising Preclinical Results and Selective Efficacy Bolster Buy RatingNovember 5, 2024 | markets.businessinsider.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.2% - Here's What HappenedORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 5.2% - Time to Sell?November 4, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a report on Monday.November 4, 2024 | marketbeat.comWells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight RecommendationNovember 1, 2024 | msn.comORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.com Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address ORIC Media Mentions By Week ORIC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORIC News Sentiment▼0.960.74▲Average Medical News Sentiment ORIC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORIC Articles This Week▼53▲ORIC Articles Average Week Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACADIA Pharmaceuticals News Today Vericel News Today Zai Lab News Today MoonLake Immunotherapeutics News Today MorphoSys News Today Bausch Health Companies News Today Merus News Today Recursion Pharmaceuticals News Today Amneal Pharmaceuticals News Today Catalyst Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORIC) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
